CM
ARRY

Crestline Management’s Array Biopharma Inc ARRY Stock Holding History

Crestline Management’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-59,291
Closed -$729K – 226
2017
Q3 		$729K Buy
+59,291
New +$551K 0.1% 113
2017
Q2 		– Sell
-52,800
Closed -$472K – 180
2017
Q1 		$472K Buy
+52,800
New +$562K 0.09% 89
2016
Q4 		– Sell
-35,715
Closed -$241K – 236
2016
Q3 		$241K Buy
+35,715
New +$138K 0.03% 176

Other funds holding ARRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Crestline Management's ARRY Position: Q4 2017 in Review

Crestline Management sold out of Array Biopharma Inc (ARRY) in Q4 2017, closing a stake of 59,291 shares — an estimated $729K sold.

Crestline Management first reported a position in ARRY in Q3 2016 and held it in 3 quarters. The position peaked at $729K in Q3 2017. 191 funds tracked by Wall St. Rank hold ARRY as of Q4 2017.

  • Crestline Management reported no remaining Array Biopharma Inc position as of Q4 2017 after selling out during the quarter.
  • Crestline Management sold 59,291 Array Biopharma Inc shares in Q4 2017, an estimated $729K.
  • Crestline Management first reported a position in Array Biopharma Inc in Q3 2016 and held it in 3 quarters.
  • Crestline Management's Array Biopharma Inc position peaked at $729K in Q3 2017.
  • 191 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q4 2017.

Based on Crestline Management's 13F filing for Q4 2017, filed 14 Feb 2018.